Hospital company Aster DM Healthcare (NSE: ASTERDM) can distribute bumper dividends to its investors. Actually, the company’s subsidiary Aster DM Health is going to sell its stake in FZC to GCC Holding Limited.
On January 15, the company informed that the board is planning to use a major part of the upfront payment in this transaction to pay dividends to its shareholders.
For this reason, the investors of the company can earn bumper income in the form of dividends.
What Information Has The Company Given?
In a letter sent to the stock exchange on January 15, Aster DM Healthcare said that the company’s board reviewed the deal for the sale of GCC business between subsidiary Affinity Holdings Private Limited and Alpha GCC Holding Limited and expressed hope that this transaction will be completed soon.
The company has informed that the board wants to use 70 to 80 percent of the upfront payment of this deal to give dividends to the investors.
This will be equivalent to a dividend of Rs 110-120 on each share. The company made it clear that the final decision on the dividend will be taken only when this transaction is completed and the company receives its amount.
The transaction is expected to be completed within this financial year.
What Is This Deal?
The corporate hospital chain Aster DM Healthcare informed the stock exchanges in November that Affinity Holdings Private Limited would sell its stake in Aster DM Healthcare FZC.
The subsidiary is selling this stake to Alpha GCC Holdings for $1.01 billion.
How Was The Stock’s Performance?
The stock closed at Rs 400 on Monday with a decline of about one percent. The stock has increased only 1 percent in the last one month.
The return on the stock in one year has been 80 percent. The stock has increased by 146 percent in 3 years.
About Aster DM Healthcare Ltd
Aster DM Health Care Limited is a provider of healthcare services. Hospitals and their in-house pharmacies are included under the Hospitals segment.
The Clinics segment consists of clinics with in-house pharmacies. Retail pharmacies include standalone retail pharmacies, optical outlets, and other retailers. The Other segment includes healthcare consulting services.
The geographical segments of the Company include the GCC states, which include the United Arab Emirates (UAE), Qatar, Oman, and the Kingdom of Saudi Arabia, Jordan, Kuwait Bahrain.
The Company’s healthcare services are offered under the Aster, Medicare, and Access brands.
Fundamental Analysis of Aster DM Healthcare Ltd
| Market Cap | ₹ 21,329 Cr. |
| Current Price | ₹ 426 |
| 52-wk High | ₹ 450 |
| 52-wk Low | 201 |
| Stock P/E | 65.7 |
| Book Value | ₹ 87.6 |
| Dividend | 0.00 % |
| ROCE | 9.21 % |
| ROE | 11.0 % |
| Face Value | ₹ 10.0 |
| P/B Value | 4.86 |
| OPM | 13.1 % |
| EPS | ₹ 5.69 |
| Debt | ₹ 5,995 Cr. |
| Debt to Equity | 1.37 |
| Year | 1st Target | 2nd Target |
| 2024 | ₹430 | ₹489 |
| 2025 | ₹500 | ₹542 |
| 2026 | ₹560 | ₹600 |
| 2027 | ₹620 | ₹680 |
| 2028 | ₹750 | ₹800 |
| 2029 | ₹820 | ₹900 |
| 2030 | ₹962 | ₹1100 |
| Promoters Holding | |
| Sept 2022 | 37.88% |
| Dec 2022 | 37.88% |
| Mar 2023 | 41.88% |
| June 2023 | 41.88% |
| Sept 2023 | 41.88% |
| FII Holding | |
| Sept 2022 | 11.77% |
| Dec 2022 | 42.49% |
| Mar 2023 | 38.63% |
| June 2023 | 38.82% |
| Sept 2023 | 40.22% |
| DII Holding | |
| Sept 2022 | 8.99% |
| Dec 2022 | 8.93% |
| Mar 2023 | 8.93% |
| June 2023 | 8.62% |
| Sept 2023 | 7.64% |
| Public Holding | |
| Sept 2022 | 40.91% |
| Dec 2022 | 10.25% |
| Mar 2023 | 10.12% |
| June 2023 | 10.26% |
| Sept 2023 | 9.85% |
| Others Holding | |
| Sept 2022 | 0.45% |
| Dec 2022 | 0.44% |
| Mar 2023 | 0.43% |
| June 2023 | 0.42% |
| Sept 2023 | 0.41% |
To gain a better understanding of how the market is performing, let’s look at the outlook of this share in the previous years.
However, investors should be aware of the risks and the market conditions before making any investment decision.
Last 5 Years’ Sales:
| 2019 | ₹7,963 Cr |
| 2020 | ₹8,652 Cr |
| 2021 | ₹8,608 Cr |
| 2022 | ₹10,253 Cr |
| 2023 | ₹12,986 Cr |
Last 5 Years’ Net Profit:
| 2019 | ₹367 Cr |
| 2020 | ₹315 Cr |
| 2021 | ₹178 Cr |
| 2022 | ₹601 Cr |
| 2023 | ₹346 Cr |
Last 5 Years’ Debt-To-Equity Ratio:
| 2019 | 0.92 |
| 2020 | 0.86 |
| 2021 | 0.57 |
| 2022 | 0.55 |
| 2023 | 0.56 |
Last 10 Years’ Profit Growth:
| 10 Years: | 16% |
| 5 Years: | 22% |
| 3 Years: | -1% |
| Current Year: | -34% |
Last 10 years’ Return on Equity (ROE):
| 10 Years: | 10% |
| 5 Years: | 12% |
| 3 Years: | 10% |
| Last Year: | 11% |
Last 10 Years’ Sales Growth:
| 10 Years: | 20% |
| 5 Years: | 12% |
| 3 Years: | 11% |
| Current Year: | 20% |
Conclusion
This article is a complete guide about Aster DM Healthcare Share.
These information and forecasts are based on our analysis, research, company fundamentals and history, experiences, and various technical analyses.
Also, We have talked in detail about the share’s future prospects and growth potential.
Hopefully, these informations will help you in your further investment.
If you are new to our website and want to get all the latest updates related to the stock market, join us on Telegram Group.
If you have any further queries, please comment below. We will be happy to answer all your questions.
If you like this information, share the article with as many people as possible.
Also Read: ₹25 Share In A Very Strong Position: Profit May Jump 705%; January 27 Result Date
Disclaimer: Dear readers, we’d like to inform you that we are not authorized by SEBI (Securities and Exchange Board of India). The information on this site is only for informational and educational purposes and shouldn’t be considered financial advice or stock recommendations. Also, the share price predictions are completely for reference purposes. The price predictions will only be valid when there are positive signs on the market. Any uncertainty about the company’s future or the current state of the market will not be considered in this study. We are not responsible for any financial loss you might incur through the information on this site. We are here to provide timely updates about the stock market and financial products to help you make better investment choices. Do your own research before any investment.
